The IPO removes near-term bankruptcy risk but the stock will trade on Phase 2b data readout in H1 2027. Watch for insider lock-up expiration (180 days) and any early exercise of the greenshoe. No revenue catalysts before the Phase 2b data.
Executive Summary
Retension Pharmaceuticals priced its IPO of 3,750,000 shares at $12.00 per share, raising gross proceeds of $45.0 million ($41.85 million net before expenses). The offering resolves a going-concern doubt and provides approximately 21 months of runway to fund the ongoing Phase 2b trial of RTN-001 in uncontrolled hypertension and prepare for a Phase 3 trial. The company is a clinical-stage biopharma with no revenue, a history of operating losses, and a single product candidate.
Key Financial Metrics
Key Facts
- IPO of 3,750,000 shares at $12.00/share = $45.0M gross proceeds
- Net proceeds to company: $41.85M before expenses; estimated net proceeds ~$38.9M after all expenses
- Underwriters: Leerink Partners, Guggenheim Securities, Oppenheimer & Co., Titan Partners
- 30-day greenshoe option for up to 562,500 additional shares
- Shares to be outstanding after offering: 8,331,599 shares (or 8,894,099 if greenshoe exercised)
- Net proceeds + existing cash ($13.5M) expected to fund operations for ~21 months
- Proceeds allocated: ~$18M to complete Phase 2b trial, ~$10M to prepare for Phase 3
- Company has a going-concern warning; accumulated deficit of $15.8M as of June 30, 2026
- Only product candidate is RTN-001, a PDE-5 inhibitor for hypertension; Phase 2b data expected H1 2027
- Material weakness in internal controls related to CRO accounting; 2025 financials restated
Financial Impact
IPO raises $45.0M gross; net ~$38.9M. Dilution of $5.75/share for new investors (IPO price $12.00 vs pro forma adjusted NAV $6.25).
Risk Factors
- Single-product clinical-stage company with no revenue and history of losses
- Going-concern warning only resolved by this IPO — additional capital still needed for Phase 3
- Phase 2b data risk — prior trials were small and conducted by a different company (Surface Logix)
- Material weakness in internal controls and 2025 restatement
- CEO and CSO have significant outside roles creating potential conflicts
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001213900-26-108587 |
| Document: 0001213900-26-108587-index-headers.html | 0001213900-26-108587 |
| Document: 0001213900-26-108587-index.html | 0001213900-26-108587 |
| Document: 0001213900-26-108587.txt | 0001213900-26-108587 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $16.55 | awaiting T+5 | — | $14.84 (−10.33%) |
Oct 16, 2026 9d ago | SC 13G | $16.33 | awaiting T+5 | — | $14.84 (−9.12%) |
Oct 16, 2026 9d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $14.84 (+5.47%) |
Oct 15, 2026 10d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.84 (+21.54%) |
Oct 14, 2026 11d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.84 (+21.54%) |
Oct 13, 2026 12d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.84 (+27.49%) |
Oct 13, 2026 12d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.84 (+27.49%) |
Oct 9, 2026 16d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $14.84 (+31.10%) |
Oct 9, 2026 17d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.84 (+40.93%) |
Oct 8, 2026 17d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.84 (+40.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers